Claims for Patent: 6,093,393

Summary for Patent: 6,093,393

Title:	Methods for preparing and using clonogenic fibroblasts and transfected clonogenic fibroblasts
Abstract:	The invention relates to a process for preparing clonogenic fibroblasts, with tissue being removed from the donor and the individual cells being isolated from the tissue, the resulting cell suspension being strained, the cells which are contained in the cell suspension being washed and the cells being converted into a tissue culture, with the exception of the isolation of individual cells by mechanical comminution, followed by an enzymic treatment with collagenase alone, and with at least one gene being inserted into the fibroblasts by means of the transfection, which gene encodes a biologically active protein, preferably a therapeutically active protein, for example a growth factor, a hormone, an enzyme, a coagulation factor or a coagulation inhibitor.
Inventor(s):	Rosenthal; Felicia (79102 Freiburg, DE), Lindemann; Albrecht (79294 Solden, DE), Boehm; Thomas (79279 Vorstetten, DE), Mertelsmann; Roland (79104 Freiburg, DE), Veelken; Hendrik (79110 Freiburg, DE), Kulmburg; Peter (79110 Freiburg, DE)
Assignee:
Application Number:	08/700,506
Patent Claims:	1. A process for producing transfected fibroblasts, comprising: (a) removing a fibroblast containing tissue sample from a subject, (b) preparing a suspension of single cells of said tissue sample, (c) washing said suspension, (d) culturing the washed cells in the presence of feeder cells selected from the group consisting of irradiated human fibroblasts and irradiated murine fibroblasts, under conditions favoring proliferation of fibroblasts from said sample to produce clonogenic fibroblasts, and (e) inserting at least one gene into said clonogenic fibroblasts wherein said gene encodes a biologically active protein. 2. The process of claim 1, wherein said biologically active protein is a therapeutically active protein. 3. The process of claim 2, wherein said therapeutically active protein is selected from the goup consisting of a growth factor, a hormone, an enzyme, a coagulation factor or a coagulation inhibitor. 4. The process of claim 3, wherein said growth factor is a hematopoietic growth factor. 5. The process of claim 1, further comprising transfecting said fibroblasts with a suicide gene. 6. The process of claim 5, wherein said suicide gene is a herpes simplex virus thymidine kinase gene. 7. The process of claim 1, wherein said gene is operably linked to a promoter. 8. The process of claim 1, wherein said gene is inserted by amethodselectedfromthegroup consisting of electroporation, microinjection, particle bombardment and lipofection. 9. The process of claim 1, wherein said fibroblasts are human fibroblasts. 10. The process of claim 1, wherein said feeder cells are allogeneic to a subject from which they are taken. 11. The process of claim 1, further comprising contacting said tissue sample with at least one enzyme selected from the group consisting of collagenase, dispase, and hyaluronidase. 12. The process of claim 7 wherein said promoter is an inducible promoter. 13. The process of claim 1 wherein said fibroblast containing tissue is a biopsy from a patient having cancer. 14. The method of claim 1 further comprising (f) isolating and expanding a transfected cell of step (e). 15. A process for producing clonogenic fibroblasts, comprising: (a) removing a fibroblast containing tissue sample from a subject, (b) preparing a suspension of single cells of said tissue sample, (c) washing said suspension, (d) culturing the washed cells in the presence of feeder cells selected from the group consisting of irradiated human fibroblasts and irradiated murie fibroblasts, under conditions favoring proliferation Qf fibroblasts from said sample to produce clonogenic fibroblasts, and (e) isolating and then expanding the isolated clonogenic fibroblasts. 16. A method for mobilizing hematopoietic cells in a subject comprising administering to a subject in need thereof an amount of a therapeutic composition comprising transfected fibroblasts produced by the method of claim 7 and a pharmaceutically acceptable carrier wherein said biologically active protein is granulocyte macrophage colony stimulating factor (GM-CSF) and wherein said amount is sufficient to mobilize hematopoietic cells. 17. The method of claim 16 wherein administering the transfected fibroblasts comprises the step of implanting a vessel prosthesis comprising a biocompatible material containing the transfected fibroblasts into said subject. 18. The method of claims 16 wherein said transfected fibroblasts are irradiated. 19. The method of claim 18 wherein administering the transfected fibroblasts comprises the step of implanting a vessel prosthesis comprising a biocompatible material containing the transfected fibroblasts into said subject. 20. A method for mobilizing hematopoietic cells in a subject comprising administering to a subject in need thereof an amount of a therapeutic composition comprising transfected fibroblasts produced by the method of claim 7 and a pharmaceutically acceptable carrier wherein said biologically active protein is granulocyte colony stimulating factor (G-CSF) and wherein said amount is sufficient to mobilize hematopoietic cells. 21. The method of claim 20 wherein said transfected fibroblasts are irradiated. 22. The method of claim 20 wherein administering the transfected fibroblasts comprises the step of implanting a vessel prosthesis comprising a biocompatible material containing the transfected fibroblasts into said subject. 23. The method of claim 21 wherein administering the transfected fibroblasts comprises the step of implanting a vessel prosthesis comprising a biocompatible material containing the transfected fibroblasts into said subject.

Details for Patent 6,093,393

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2014-02-24
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2014-02-24
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2014-02-24
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2014-02-24
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-02-24